Catalent, Inc. (CTLT)
After hours:
- Motley Fool
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.
- Zacks
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
- Zacks
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
